HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Equity Capital Markets

Yantai Lannacheng Biotechnology / Equity Capital Markets

<ul>
<li>The gap in nuclear medicine between China and international community is several decades. The reasons behind are complex and fatal. Lanacheng is a biotech with "high potential and high risk".</li>
<li>Various requirements pose extremely high challenges to commercialization in the nuclear medicine industry. The mature and complete upstream to downstream industrial chain of nuclear medicine itself has high barriers.</li>
<li>Investors need to recognize the risks of Lanacheng's products not being commercialized or the commercialization largely fall short of expectations, thus leading to continuous losses.Valuation would be lower than peer.</li>
</ul>


The gap in nuclear medicine between China and international community is several decades. The reasons behind are complex and fatal. Lanacheng is a biotech with "high potential and high risk".
Various requirements pose extremely high challenges to commercialization in the nuclear medicine industry. The mature and complete upstream to downstream industrial chain of nuclear medicine itself has high barriers.
Investors need to recognize the risks of Lanacheng's products not being commercialized or the commercialization largely fall short of expectations, thus leading to continuous losses.Valuation would be lower than peer.


Pre-IPO Yantai Lannacheng Biotechnology - There Is Still a Long Way to Go

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Yantai Lannacheng Biotechnology (YLB HK)

Pre-IPO Yantai Lannacheng Biotechnology - There Is Still a Long Way to Go

China's nuclear medicine industry faces significant challenges, with Lanacheng being a high-risk target due to commercialization issues. The...

Xinyao (Criss) Wang

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Pre-IPO Yantai Lannacheng Biotechnology - There Is Still a Long Way to Go

​China's nuclear medicine industry faces significant challenges, with Lanacheng being a high-risk target due to commercialization issues. The...

Xinyao (Criss) Wang

China's nuclear medicine industry faces significant challenges, with Lanacheng being a high-risk target due to commercialization issues. The...